Cite

Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

MLA

UCL - (MGD) Service d’hématologie, et al. “Phase II Study of Oral JAK1/JAK2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory Hodgkin Lymphoma.” Haematologica : The Hematology Journal, Vol. 103, No. 5, p. 840-848 (2018), 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130455161&authtype=sso&custid=ns315887.



APA

UCL - (MGD) Service d’hématologie, UCL - (SLuc) Service d’hématologie, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/GEHU - Génétique, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Ucl - Sss, I.-P. d’imagerie moléculaire, radiothérapie et oncologie, Van Den Neste, E., André, M., Gastinne, T., Stamatoullas, A., Haioun, C., Belhabri, A., Reman, O., Casasnovas, O., Guesquieres, H., … Morschhauser, F. (2018). Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica : The Hematology Journal, Vol. 103, No. 5, p. 840-848 (2018).



Chicago

UCL - (MGD) Service d’hématologie, UCL - (SLuc) Service d’hématologie, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/GEHU - Génétique, et al. 2018. “Phase II Study of Oral JAK1/JAK2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory Hodgkin Lymphoma.” Haematologica : The Hematology Journal, Vol. 103, No. 5, p. 840-848 (2018). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130455161&authtype=sso&custid=ns315887.